Nuprin is a Small Molecule owned by Johnson & Johnson, and is involved in 11 clinical trials, of which 10 were completed, and 1 is planned.

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. It inhibits the activity of cyclooxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase (cyclooxygenase). Prostaglandins are produced due to injury and certain diseases conditions causing pain, swelling, fever and inflammation. The mechanism of action of ibuprofen in patent ductus arteriosus (PDA) is through inhibition of prostaglandin synthesis, resulting in ductal constriction.

The revenue for Nuprin is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nuprin NPV Report.

Nuprin is currently owned by Johnson & Johnson.

Nuprin Overview

Ibuprofen (Perdophen, Perdofemina, Montrin, Nuprin, Calprofen, Dolormin, Doctril) is an analgesic, antipyretic and anti-inflammatory agent. It is formulated as a tablet, film coated tablets, capsules and soft gelatin capsules, suspension and effervescent granules, chewable tablets for oral administration ans suppositories for rectal administration. Ibuprofen is used for relief from signs and symptoms of rheumatoid arthritis and osteoarthritis, temporary relief of minor aches and pains inmuscles, bones and joints, headache, fever,the aches and fever due to the common cold or flu, immunizations, toothache (dental pain), sore throat and ear ache.

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Nuprin

Report Segments
  • Innovator (NME)
Drug Name
  • Nuprin
Administration Pathway
  • Oral
  • Rectal
Therapeutic Areas
  • Central Nervous System
  • Ear Nose Throat Disorders
  • Other Diseases
  • Respiratory
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.